Hemophilia A Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Genentech, Novo Nordisk, Pfizer, Sanofi, Shire, ApcinteX, CSL Behring, Freeline Therapeutics, ASC Therapeutics, Ultragenix Pha

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hemophilia A pipeline constitutes 35+ key companies continuously working towards developing 45+ Hemophilia A treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Hemophilia A Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hemophilia A Market.

The Hemophilia A Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Hemophilia A Pipeline Report: https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Hemophilia A treatment therapies with a considerable amount of success over the years.
• Hemophilia A companies working in the treatment market are Generation Bio, Poseida Therapeutics, Expression Therapeutics, Chugai Pharmaceutical, ASC Therapeutics, Ascension, Staidson (Beijing) Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, Novo Nordisk, Pfizer, and others, are developing therapies for the Hemophilia A treatment
• Emerging Hemophilia A therapies in the different phases of clinical trials are- Research program: Gene Therapies, P-FVIII-101, ET3 lentiviral gene therapy, NXT007, ASC618, SelectAte, STSP-0601, TQG 203, Mim8, Giroctocogene fitelparvovec, and others are expected to have a significant impact on the Hemophilia A market in the coming years.
• In January 2023: worldwide biotechnology business BioMarin Pharmaceutical Inc., committed to improving lives through genetic research, released encouraging findings from its ongoing worldwide Phase 3 GENEr8-1 study of ROCTAVIANTM (valoctocogene roxaparvovec) after more than three years of follow-up. An experimental one-time gene therapy is being used to treat adults with severe hemophilia A. With 134 participants, it is the largest and most extensive global Phase 3 study for any gene treatment in hemophilia.In February 2023, For adults and children with hemophilia A, the US FDA approved ALTUVIIIO (efanesoctocog alfa) as a factor VIII replacement medication. For adults and children with hemophilia A, ALTUVIIIO is recommended for perioperative management (surgery), routine prophylaxis, and on-demand medication to control bleeding episodes.
• In September 2022, Reopening recruitment for the Phase III AFFINE trial, which is assessing giroctocogene fitelparvovec, is a joint announcement from Pfizer and Sangamo Therapeutics.
• In August 2022, For the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult patients without a history of Factor VIII inhibitors and without detectable antibodies to adeno-associated virus serotype 5, the European Commission (EC) granted conditional marketing permission to ROCTAVIAN gene therapy.

Hemophilia A Overview
A genetic bleeding illness called hemophilia A, or classical hemophilia, is brought on by low amounts of a blood protein called factor VIII. Hemophilia A patients will bleed more profusely following an injury, procedure, or surgery.

Get a Free Sample PDF Report to know more about Hemophilia A Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/hemophilia-a-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Hemophilia A Drugs Under Different Phases of Clinical Development Include:
• Research program: Gene Therapies: Generation Bio
• P-FVIII-101: Poseida Therapeutics
• ET3 lentiviral gene therapy: Expression Therapeutics
• NXT007: Chugai Pharmaceutical
• ASC618: ASC Therapeutics
• SelectAte: Ascension
• STSP-0601: Staidson (Beijing) Biopharmaceutic als
• TQG 203: Chia Tai Tianqing Pharmaceutical Group
• Mim8: Novo Nordisk
• Giroctocogene fitelparvovec: Pfizer

Hemophilia A Route of Administration
Hemophilia A pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Hemophilia A Molecule Type
Hemophilia A Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Hemophilia A Pipeline Therapeutics Assessment
• Hemophilia A Assessment by Product Type
• Hemophilia A By Stage and Product Type
• Hemophilia A Assessment by Route of Administration
• Hemophilia A By Stage and Route of Administration
• Hemophilia A Assessment by Molecule Type
• Hemophilia A by Stage and Molecule Type

DelveInsight's Hemophilia A Report covers around 45+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Hemophilia A product details are provided in the report. Download the Hemophilia A pipeline report to learn more about the emerging Hemophilia A therapies at:
https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Hemophilia A Therapeutics Market include:
Key companies developing therapies for Hemophilia A are - ApcinteX, ASC Therapeutics, Ultragenix Pharmaceutical, BioMarin Pharmaceutical, CSL Behring, Freeline Therapeutics, Genentech, Inc., Novo Nordisk, Pfizer, Sanofi, Shire, Spark Therapeutics, Amarna therapeutics, Asklepios BioPharmaceutical, Bayer, Belief Biomed, Bioverativ, Catalyst Biosciences, Centessa Pharmaceuticals, Chameleon Biosciences, Chia Tai Tianqing Pharmaceutical Group, Expression Therapeutics, GC Pharma, GeneVentiv, Intellia tx, OPKO Health, Sangamo Therapeutics, Staidson Beijing BioPharmaceuticals, UBI Pharma, uniQure, and others.

Hemophilia A Pipeline Analysis:
The Hemophilia A pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Hemophilia A with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemophilia A Treatment.
• Hemophilia A key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hemophilia A Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hemophilia A market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Hemophilia A drugs and therapies-
https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hemophilia A Pipeline Market Drivers
• Increasing number of hemophilic patients worldwide, increasing development of novel therapies, increasing diagnostic rate are some of the important factors that are fueling the Hemophilia A Market.

Hemophilia A Pipeline Market Barriers
• However, side effects associated with the plasma derived products, high cost of recombinant products and other factors are creating obstacles in the Hemophilia A Market growth.

Scope of Hemophilia A Pipeline Drug Insight
• Coverage: Global
• Key Hemophilia A Companies: Generation Bio, Poseida Therapeutics, Expression Therapeutics, Chugai Pharmaceutical, ASC Therapeutics, Ascension, Staidson (Beijing) Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, Novo Nordisk, Pfizer, and others
• Key Hemophilia A Therapies: Research program: Gene Therapies, P-FVIII-101, ET3 lentiviral gene therapy, NXT007, ASC618, SelectAte, STSP-0601, TQG 203, Mim8, Giroctocogene fitelparvovec, and others
• Hemophilia A Therapeutic Assessment: Hemophilia A current marketed and Hemophilia A emerging therapies
• Hemophilia A Market Dynamics: Hemophilia A market drivers and Hemophilia A market barriers

Request for Sample PDF Report for Hemophilia A Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Hemophilia A Report Introduction
2. Hemophilia A Executive Summary
3. Hemophilia A Overview
4. Hemophilia A- Analytical Perspective In-depth Commercial Assessment
5. Hemophilia A Pipeline Therapeutics
6. Hemophilia A Late Stage Products (Phase II/III)
7. Hemophilia A Mid Stage Products (Phase II)
8. Hemophilia A Early Stage Products (Phase I)
9. Hemophilia A Preclinical Stage Products
10. Hemophilia A Therapeutics Assessment
11. Hemophilia A Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Hemophilia A Key Companies
14. Hemophilia A Key Products
15. Hemophilia A Unmet Needs
16 . Hemophilia A Market Drivers and Barriers
17. Hemophilia A Future Perspectives and Conclusion
18. Hemophilia A Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Hemophilia A Market https://www.delveinsight.com/report-store/hemophilia-a2030-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Hemophilia A Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Hemophilia A Epidemiology https://www.delveinsight.com/report-store/hemophilia-a-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Hemophilia A Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market
Ventricular Assist Devices Market By Product Type (Left Ventricular Assist Devices, Right Ventricular Assist Devices, And Biventricular Assist Devices), By Application Type (Bridge-To-Transplant [Btt], Destination Therapy, And Others), By Design Type (Transcutaneous Ventricular Assist Devcies And Implantable Ventricular Assist Devices), By Type Of Flow (Pulsatile Flow And Continous Flow), By End User (Hospital And Clinics, Ambulatory Surgical Centers, And Others), by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of heart failure and cardiovascular diseases due to obesity, age, & unhealthy lifestyles and rising demand for organ transplants due to increasing prevalence of chronic ailments such as hypertension, diabetes, and others

B-cell Non-hodgkin Lymphoma Market https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-market
DelveInsight's "B-Cell Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Non-Hodgkin Lymphoma, historical and forecasted epidemiology as well as the B-Cell Non-Hodgkin Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Systemic Sclerosis Market
https://www.delveinsight.com/report-store/systemic-sclerosis-market
DelveInsight's "Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes Systemic Sclerosis. The report includes a detailed examination of the historical and projected epidemiology data that includes diagnosed prevalent cases of Systemic Sclerosis segmented by gender-specific, age-specific, and type-specific cases.

Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
"DelveInsight's 'Resorbable Vascular Scaffolds Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vascular Stents Market
https://www.delveinsight.com/report-store/vascular-stents-market
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market
https://www.delveinsight.com/report-store/vein-illumination-devices-market
"DelveInsight's 'Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products.

Symptomatic Partial-thickness Rotator Cuff Tears Market
https://www.delveinsight.com/report-store/symptomatic-partial-thickness-rotator-cuff-tears-market
DelveInsight's "Symptomatic Partial-thickness Rotator Cuff Tears Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Symptomatic Partial-thickness Rotator Cuff Tears, historical and forecasted epidemiology as well as the Symptomatic Partial-thickness Rotator Cuff Tears market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market
https://www.delveinsight.com/report-store/zika-virus-market
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.